Biorce
Category: AI in Healthcare
An AI-native platform designed to automate and optimize the entire clinical trial lifecycle, from protocol design and feasibility analysis to site selection and execution. Biorce was founded in 2024. The company is led by Pedro Coelho. Based in Barcelona, Spain (HQ: Edifici Dau, Av. Diagonal 615); Austin, TX (823 Congress Ave) & New York, NY (205 W 37th St) US offices. Team size: 101-500. Total funding raised: $62.5M. Latest round: Series A. Key investors include DST Global Partners, Norrsken VC, YZR Capital, Mustard Seed Maze, Endeavor Catalyst, Nik Storonsky (CEO of Revolut), Arthur Mensch (CEO of Mistral AI), Paulo Rosado (Founder of OutSystems), Albert Nieto (Founder of Seedtag).
AMW Analysis
Biorce is an AI-native platform that automates the clinical trial lifecycle, covering protocol design, feasibility analysis, site selection, and execution. Its value proposition centers on reducing trial setup and protocol development from months to minutes while improving data accuracy and lowering failure rates. The company raised $52.5 million in Series A funding in February 2026 to scale its Aika platform, which generates regulator-ready protocols in 90 seconds by leveraging one million historical trials. The funding supports expansion into Austin, Texas, and New York, reflecting a shift toward regulatory-ready, human-in-the-loop AI models. Biorce aims to cut drug development timelines and costs by 50 percent, addressing protocol amendments that delay 57 percent of studies. The record investment, backed by DST Global Partners, Norrsken VC, and individual investors including the CEOs of Revolut and Mistral AI, positions the company to target $120 billion in annual inefficiencies in clinical research.
AMW analysis, generated from 2 tracked news signals.
- Founded
- 2024
- Headquarters
- Barcelona, Spain (HQ: Edifici Dau, Av. Diagonal 615); Austin, TX (823 Congress Ave) & New York, NY (205 W 37th St) US offices
- Team size
- 101-500
- Total funding
- $62.5M
Value proposition
Reduces clinical trial setup and protocol development time from months to minutes while increasing data accuracy and reducing the high failure rates associated with manual trial design.
Products and solutions
Aika 2.0: AI-native clinical development operating system (end-to-end from portfolio decision to regulatory submission), Automated Protocol Design: Generative AI for regulator-ready protocols (minutes vs months; ~86% accuracy claimed), AI Feasibility, Patient Identification, Budgets & Contracts modules, Site Selection, Monitoring, Regulatory & Submission orchestration across ~1M historical trials
Unique value
Biorce is built as an 'AI-native' company rather than a legacy CRO adding AI features; its platform, Aika, treats clinical data as a dynamic ecosystem to solve structural inefficiencies in drug development.
Target customer
Global pharmaceutical companies, emerging biotechnology firms, and Contract Research Organizations (CROs).
Industries served
Healthcare, Biotechnology, Pharmaceuticals, Life Sciences
Technology advantage
Leverages proprietary generative AI models trained on ~1M clinical trials to automate protocol design, feasibility, and documentation with explainable outputs; backed by a leadership team with deep CRO/clinical-operations and engineering expertise (ex-Talentmark CRO, Microsoft, pharma clinical ops).
How they differentiate
Biorce differentiates through its 'AI-native' architecture, specifically its Aika platform, which automates the entire clinical trial lifecycle—from protocol design to site selection—reducing setup times from months to minutes. Unlike legacy providers that add AI features to old systems, Biorce uses generative AI to treat clinical data as a dynamic ecosystem.
Main competitors
Unlearn.AI, QuantHealth, Medidata (Dassault Systèmes), Veeva Systems
Key partnerships
DST Global Partners (Lead Investor), Norrsken VC, Strategic R&D presence in the United States, Technical backing from industry leaders including Arthur Mensch (CEO of Mistral AI) and Nik Storonsky (CEO of Revolut)
Notable customers
Global Pharmaceutical Companies, Emerging Biotechnology Firms, Contract Research Organizations (CROs)
Major milestones
Founded 2024 in Barcelona by Pedro Coelho, Clara Bernardes, José Faria, Diogo Pisoeiro, Raised €3.5M Seed (Nov 2024, YZR Capital / Mustard Seed Maze) then €5M Seed extension (Jul 2025, Norrsken VC), Secured $52.5M Series A led by DST Global Partners (announced Feb 2, 2026) — largest Iberian healthtech Series A, Relocated Barcelona HQ to Edifici Dau (former AstraZeneca offices, Av. Diagonal 615), Opened US offices in New York (WeWork, 205 W 37th St) and Austin R&D hub at 823 Congress Ave, Won 4YFN26 Award at Mobile World Congress (March 2026), Launched Aika 2.0 clinical development OS; showcased at BIO 2026 (Jul 2026)
Growth metrics
Largest Series A in Iberian healthtech (~$52.5M, Feb 2026); targeting ~250 employees by end-2026; ~€10M revenue in first year on market (EL PAÍS, May 2026); ended 2025 ~200% above revenue target; headcount ~172 (Tracxn Jul 2026) / ~180–183 (PitchBook/LinkedIn Sep 2026), up from >120 in Apr 2026.
Market positioning
High-growth AI disruptor in the Clinical Research Organization (CRO) and Clinical Trial Management System (CTMS) space.
Geographic focus
Europe (Headquarters in Barcelona) and North America (Strategic R&D and commercial expansion).
Patents and IP
Proprietary AI architecture and trade secrets; no specific public patent filings disclosed as of February 2025.
About Pedro Coelho
Pedro Coelho is Founder & CEO of Biorce (founded 2024). Portuguese entrepreneur (~age 30 as of May 2026) with ~8+ years in life sciences; previously Senior Vice President at Talentmark, where he built TMFS, a CRO focused on Oncology and Cell & Gene Therapy, after roles in clinical-trial consulting/BD. Education: Business Administration (Summa Cum Laude, EU Business School); executive education at Harvard Medical School and the University of Pennsylvania. Motivated by his father's melanoma diagnosis and delayed trial access.
Latest news about Biorce
- Biorce secured 52.5 million USD in Series A funding to scale Aika, an AI platform that generates regulator ready protocols in 90 seconds. Leveraging one million historical trials, it aims to cut drug
- Barcelona based Biorce secured 43.8 million Euro in Series A funding to scale its Aika AI platform. By leveraging 1 million trials, the system aims to slash trial costs and timelines by 50 percent, ad
More AI in Healthcare companies
Official website: https://www.biorce.com/
